Objectives and unmet need:
The management of MS is becoming increasingly complex with different treatment paradigms and the emergence of several new disease-modifying therapies with different modes of action and monitoring requirements. This meeting addresses an unmet need on how we use and derisk these treatments in clinical practice, including emerging and changing treatment targets, the emergence of new biomarkers and whether or not HSCT, arguably our most effective treatment, should be made available very early in the course of MS. The issues that are being addressed in this meeting are controversial and not covered in easy-to-access journal articles, which makes this meeting very appealing to HCPs specialising in MS, who work on the NHS coalface and have to deal with these issues on a daily basis.
Example programme, which will be confirmed with sessions closer to the event to ensure Cutting Edge sessions are covered.
Speakers are only for illustration purposes and are not confirmed speakers or topics.
This activity has been supported by sponsorship from Biogen Idec Ltd. The sponsor has had no control over the educational content of this activity.